Physician profile
Muhammad Anis
NPI 1316971666
$2,038.82
in general payments reported to CMS, 2019-2025
21 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $226 · 2021: $98.09 · 2022: $293 · 2023: $175 · 2024: $624 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $268.05 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $264.09 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $250.66 | 2021-2025 | |
| Vifor Pharma, INC. | $246.67 | 2019-2025 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.91 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $109.53 | 2023-2025 | |
| Amgen INC. | $108.73 | 2019-2025 | Krystexxa |
| Akebia Therapeutics INC | $106.59 | 2020-2025 | Auryxia, Vafseo |
| Ardelyx, INC. | $91.82 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $81.69 | 2019-2025 | Velphoro |
| Travere Therapeutics, INC. | $78.91 | 2022-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $61.46 | 2020-2024 | |
| Horizon Therapeutics Plc | $43.37 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $39.17 | 2022 | |
| Glaxosmithkline, LLC. | $30.83 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.42 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $26.36 | 2020 | |
| Daiichi Sankyo INC. | $23.17 | 2020 | |
| Mallinckrodt Enterprises LLC | $20.92 | 2019 | |
| Shire North American Group INC | $20.38 | 2019 | |
| Genzyme Corporation | $17.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Anis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.